{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51","upperLimit":"63","value":"57"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35","upperLimit":"47","value":"41"}]}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"description":"PFS rate was defined as the percentage of participants who were alive and have not had disease progression at 12 months and 24 months after the date of start of study treatment. PFS was assessed by IMWG Criteria (2014 version). Per IMWG criteria, PD: serum M-component increase ≥ 0.5 g/dl or urine M-component increase ≥ 200 mg/24-hour/ difference between involved and uninvolved FLC levels increase \\>10 mg/dl or bone marrow plasma cell ≥ 10%/ development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"12 months and 24 months","title":"PFS Rate at 12 Months and 24 Months After the Start of Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}